Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTAP101 in Secondary Hyperparathyroidism with Vitamin D Insufficiency and CKD
NCT03602261Phase 2Terminated
- Sponsor
- OPKO Health
- Start
- Jul 2018
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial in secondary hyperparathyroidism (SHPT), Vitamin D deficiency (VDD) and chronic kidney disease (CKD) comparing CTAP101 Capsules 900mcg/weekly with Placebo Capsules weekly (2 arms). Primary endpoints: Number of Participants With Response During Efficacy Assessment Period at 26 weeks, Total 25-hydroxyvitamin D Response Analysis During Efficacy Period at 26 weeks and 4 more. Started Jul 2018; status: terminated.
02
Drugs
calcifediol
03
Conditions
secondary hyperparathyroidism (SHPT)Vitamin D deficiency (VDD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03602261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602261.